Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | The problems arising in ASO clinical trials and future preparations

Joaquim Ferreira • 4 Sep 2020
MDS 2020
Huntington’s Disease Movement Disorders

Joaquim Ferreira, MD, PhD, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, discusses the problems over administration methods and dosage of antisense oligonucleotides (ASOs) that are currently in clinical trials. Despite positive results in the early stages of the clinical trials, Prof. Ferreira says to be prudent and start preparing follow-up trials to gather additional information. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).

More from Joaquim Ferreira

1:43
Update on the ADOPTION study: opicapone in Parkinson’s disease
Joaquim Ferreira • 29 Aug 2023
1:19
Combining non-pharmacological treatments with pharmacotherapies for PD
Joaquim Ferreira • 29 Aug 2023
1:49
How dose and regimen impact levodopa bioavailability
Joaquim Ferreira • 29 Aug 2023
2:24
The importance of clinical trials in generating evidence for safe and effective therapies
Joaquim Ferreira • 29 Aug 2023

Related Videos

1:58
Ambroxol & other targeted therapies in Parkinson's
K Ray Chaudhuri • 21 Mar 2024
3:00
The use of precision medicine in Parkinson’s disease
K Ray Chaudhuri • 21 Mar 2024
0:58
Top innovations: closed-loop deep brain stimulation devices for movement disorders
Alvaro Sanchez Ferro • 2 Jul 2023
3:04
The future of regenerative medicine: overcoming immunosuppression requirements
Alfonso Fasano • 19 Oct 2023
The content of VJNeurology is intended for healthcare professionals